Nurix Therapeutics, Inc.

NASDAQ:NRIX

Biotechnology

Healthcare
$14.10 +0.85%

+$0.15 today

Market cap
$1.54B
Beta
1.87
P/E (TTM)
-6.4
EPS (TTM)
-$2.68
52W Low $8.20High $22.50

Volume 2.79M

Average 1.74M

Income Statement

Follow revenue through to earnings.

Revenue

$83.98M

FY 2025 · Annual

+54.0% YoY

Operating Income

-$285.67M

FY 2025 · Annual

Net Income

-$264.46M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Nov 2021
FY2022
Nov 2022
FY2023
Nov 2023
FY2024
Nov 2024
FY2025
Nov 2025
Revenue29.75M38.63M76.99M54.55M83.98M
Cost of Revenue116.43M184.5M189.15M221.63M18.86M
Gross Profit(86.68M)(145.87M)(112.16M)(167.08M)65.12M
Gross Margin-291.4%-377.6%-145.7%-306.3%77.5%
Research & Development116.43M184.5M189.15M221.63M308.16M
Selling, General & Admin31.2M38M42.9M45.94M52.74M
Operating Expenses31.2M38M42.9M45.94M350.79M
Depreciation & Amortization6.08M10.81M13.65M16.43M18.86M
EBITDA(110.98M)(169.55M)(130.29M)(176.87M)(244.84M)
EBITDA Margin-373.0%-438.9%-169.2%-324.2%-291.5%
Operating Income(117.89M)(183.87M)(155.06M)(213.03M)(285.67M)
Operating Margin-396.3%-476.0%-201.4%-390.5%-340.2%
Interest Income823K3.51M11.12M19.73M21.97M
Interest Expense00000
Other Income / Expenses823K3.51M11.12M19.73M21.97M
Income Before Tax(117.06M)(180.36M)(143.95M)(193.3M)(263.7M)
Pre-Tax Margin-393.5%-466.9%-187.0%-354.4%-314.0%
Income Tax Expense131K00270K760K
Net Income(117.19M)(180.36M)(143.95M)(193.57M)(264.46M)
Net Margin-393.9%-466.9%-187.0%-354.9%-314.9%
EPS (Basic)(2.73)(3.71)(2.65)(2.88)(3.05)
EPS (Diluted)(2.73)(3.71)(2.65)(2.88)(3.05)
Weighted Avg Shares42.9M48.61M54.34M67.12M86.67M
Weighted Avg Shares (Diluted)42.9M48.61M54.34M67.12M86.67M

NRIX Earnings Waterfall · TTM

NASDAQ:NRIX · Revenue to Net Income

Key Ratios

EPS$2.31
Gross Margin-255.7%
Net Margin-719.7%
P/E Ratio-3.6
P/S Ratio154.4

Analysis

$701.9M of revenue converted into $294.9M of net income for the selected period. Gross margin is -255.7% and net margin is -719.7%, showing how much revenue survives after costs and taxes. EPS is $2.31, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 5, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
4Statement of changes in beneficial ownershipNov 4, 2026
8-KCurrent reportNov 3, 2026
4Statement of changes in beneficial ownershipNov 2, 2026

How much revenue does NRIX generate?

Nurix Therapeutics, Inc. (NRIX) reported $83.98M of revenue in fiscal 2025.

Is NRIX profitable?

Nurix Therapeutics, Inc. (NRIX) reported -$264.46M of net income, with a net margin of -314.9%.